Tests LVIVO-TaVec400 in adults with relapsed or refractory multiple myeloma
Tests the LVIVO-TaVec400 product in adults with multiple myeloma that has returned or not responded.
Plain-language title generated from the registry record
Registry title: A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）
Key facts
- Where
- Beijing, Nanchang, Tianjin, Wuhan, Xuzhou, and Zhengzhou, ChinaSee the 6 sites
- Phase
- Early phase 1
Where in China
- Beijing Gobroad Boren HospitalBeijing, ChinaNo longer taking part
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNo longer taking part
- Institute of Hematology & Blood Diseases HospitalTianjin, ChinaNo longer taking part
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaNo longer taking part
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaNo longer taking part
- Henan Cancer HospitalZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT07399444
- Record updated
- 10 February 2026
- Original description
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.Read full original descriptionShow less
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the LVIVO-TaVec400 Product in the Treatment of Relapsed/Refractory Multiple Myeloma
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory multiple myeloma.
Inclusion: Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up; Age ≥ 18 years; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Has measurable lesions; Relapsed and/or refractory multiple myeloma; Life expectancy≥ 3 months; Clinical laboratory values meet screening visit criteria; Adequate organ function.
Exclusion: Prior antitumor therapy with insufficient washout period ; Those who have experienced life-threatening allergic reactions, hypersensitivity reactions or intolerances to the excipients and related additives of the investigational drug; or those with a previous history of severe allergic reactions (such as hypersensitivity reactions, or those for whom the investigator assesses the need to use glucocorticoids to prevent severe immune-related reactions such as allergic reactions); Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab); Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study; Also enrolled in other clinical studies.